Clinical outcome of 27 imatinib mesylate-resistant chronic myelogenous leukemia patients harboring a T315I BCR-ABL mutation

We analyzed 27 CML patients treated with imatinib (IM) who developed a BCR-ABLT315I mutation. These patients had poor prognostic features: High or intermediate Sokal index (82%), and lack of CCyR under IM (59%). At T315I discovery, patients were in advanced phase (59%), with clonal evolution (84%)....

Descripció completa

Dades bibliogràfiques

Autors principals:	Franck E. Nicolini, Sandrine Hayette, Selim Corm, Emmanuel Bachy, Dominique Bories, Michel Tulliez, François Guilhot, Laurence Legros, Frédéric Maloisel, Jean-Jacques Kiladjian, François-Xavier Mahon, Quoc-Hung Lê, Mauricette Michallet, Catherine Roche-Lestienne, Claude Preudhomme
Format:	Artigo
Idioma:	Inglês
Publicat:	Ferrata Storti Foundation 2007-09-01
Col·lecció:	Haematologica
Accés en línia:	https://haematologica.org/article/view/4565
Etiquetes:	Afegir etiqueta Sense etiquetes, Sigues el primer a etiquetar aquest registre!